cliffwatch

calcifediol · Eirgen · NDA 208010

Rayaldee

Earliest generic entry, as listed
14 Mar 2034

Blocked by patent: US 10300078, US 10357502, US 11253528, US 9861644.

Listed patents · 22 unexpired

PatentClaimsExpires
US 10300078product14 Mar 2034
US 10357502product14 Mar 2034
US 11253528product14 Mar 2034
US 9861644product14 Mar 2034
US 11801253product, use U-37237 Sep 2030
US 11801253product, use U-37217 Sep 2030
US 11801253product, use U-37227 Sep 2030
US 8426391use U-187227 Aug 2028
US 8361488product19 Jul 2028
US 11154509use U-381525 Apr 2028
US 8207149use U-187125 Apr 2028
US 8778373use U-187325 Apr 2028
US 9408858use U-188825 Apr 2028
US 9498486use U-381425 Apr 2028
US 9925147product, use U-225625 Apr 2028
US 9925147product, use U-225525 Apr 2028
US 9925147product, use U-225825 Apr 2028
US 9925147product, use U-225925 Apr 2028
US 9925147product, use U-225725 Apr 2028
US 10213442product2 Feb 2027
US 8906410product2 Feb 2027
US 9943530use U-22742 Feb 2027

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 1

NDA · productFormStrengthListed expiry
208010 · 001 · RLDcapsule, extended release, oral0.03MG14 Mar 2034